Trials / Active Not Recruiting
Active Not RecruitingNCT05901649
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Prospective, Multi-Country, Observational Study of Clinical Outcomes for Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With ADT Plus Apalutamide or Enzalutamide Under Routine Clinical Practice (ArtemisPRO)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 504 (actual)
- Sponsor
- Janssen-Cilag Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the real-world outcomes differences between apalutamide or enzalutamide plus androgen deprivation therapy (ADT) for the treatment of participants with metastatic hormone-sensitive prostate cancer (mHSPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apalutamide | No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice. |
| DRUG | Enzalutamide | No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice. |
Timeline
- Start date
- 2023-07-05
- Primary completion
- 2026-06-05
- Completion
- 2026-06-05
- First posted
- 2023-06-13
- Last updated
- 2026-04-13
Locations
53 sites across 6 countries: Austria, France, Germany, Greece, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT05901649. Inclusion in this directory is not an endorsement.